[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myofascial-pain-dysfunction-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myofascial-pain-dysfunction-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,53,94,113,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100635047","phase-4-prp-vs-prpbetamethasone-vs-betamethasone-injection-for-upper-trapezius-myofascial-pain-100635047",false,"NCT07547605","PRP vs PRP+Betamethasone vs Betamethasone Injection for Upper Trapezius Myofascial Pain","Comparison of Platelet-Rich Plasma, Combined Platelet-Rich Plasma Plus Betamethasone, and Betamethasone Monotherapy Trigger Point Injections in Patients With Upper Trapezius Myofascial Pain Syndrome: A Prospective, Randomized, Assessor-Blind, Controlled Trial","UMAY-RCT","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Presentation to the Orthopedics and Traumatology outpatient clinic with neck and\u002For shoulder pain\n* Diagnosis of upper trapezius myofascial pain syndrome based on Simons and Travell criteria, including:\n* Presence of a taut band\n* Local tenderness\n* Referred pain pattern\n* Local twitch response\n* Presence of a single active trigger point in the upper trapezius muscle\n* Symptom duration ≥ 4 weeks\n* Pain intensity ≥ 4 on the visual analog scale (VAS)\n* Inadequate response to at least 4 weeks of conservative treatment (physical therapy and\u002For oral analgesics)\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Presence of multiple active trigger points\n* Diagnosis of fibromyalgia according to ACR 2010 criteria\n* Cervical radiculopathy or myelopathy\n* Trigger point injection in the same region within the past 3 months\n* Coagulopathy or current anticoagulant or antiplatelet therapy\n* Known allergy or contraindication to corticosteroids, local anesthetics, or PRP components\n* Active infection (systemic or local)\n* Pregnancy or lactation\n* Thrombocytopenia (platelet count \\\u003C 100,000\u002FµL)\n* Malignancy\n* Inability to cooperate or provide informed consent","ALL","18 Years","65 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Brief Summary\n\nMyofascial pain syndrome (MPS) is a common musculoskeletal condition characterized by active trigger points (TrPs), which are hypersensitive, painful nodules within taut bands of skeletal muscle. The upper trapezius muscle is one of the most frequently affected sites. Trigger point injection (TPI) is a widely used minimally invasive treatment for patients who are refractory to conservative management.\n\nCorticosteroids provide rapid anti-inflammatory effects, whereas platelet-rich plasma (PRP) has regenerative properties through growth factors that may support tissue healing. Despite their widespread use, the optimal injectate for TPI remains unclear. Additionally, the potential benefit of combining PRP with corticosteroids has not been adequately studied in upper trapezius MPS.\n\nThis study is a single-center, prospective, randomized, assessor-blinded controlled trial designed to compare the clinical effectiveness of three injection protocols: (1) PRP plus bupivacaine, (2) PRP plus betamethasone plus bupivacaine, and (3) betamethasone plus bupivacaine with saline (volume-matched control). A total of 150 patients with a single active trigger point in the upper trapezius will be included.\n\nThe primary outcome is pain intensity measured by the visual analog scale (VAS) at 3 months. Secondary outcomes include pressure pain threshold (PPT), cervical range of motion (ROM), rescue analgesic use, recurrence rate, and adverse events at 1 week, 4 weeks, 3 months, and 6 months.\n\nAll injections are performed by the same investigator using a palpation-guided technique, and outcome assessments are conducted by a blinded evaluator.",[28,29,30],"Myofascial Pain Dysfunction Syndrome","Trigger Points, Myofascial","Trigger Point in Trapezius Muscle",[32,33,34,35,36,37,38,39],"platelet-rich plasma","PRP","betamethasone","trigger point injection","myofascial pain syndrome","trapezius","randomized controlled trial","pressure pain threshold","RECRUITING","2026-06-14",{"date":43,"type":44},"2026-06-16","ACTUAL",{"date":46,"type":44},"2026-05-15",{"date":48,"type":22},"2027-01",{"name":50,"class":51},"University of Kyrenia","OTHER",2,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":73,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100637000","evaluation-of-the-effect-of-adding-sodium-bicarbonate-to-lidocaine-in-the-treatment-of-myofascial-pain-syndrome-100637000","NCT07572994","Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndrome","Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndrome Using Surface Electromyography (sEMG)","BIC-LIDO-MPS","Inclusion Criteria:\n\nPatients aged 16 to 70 years Clinical diagnosis of myofascial pain syndrome (MPS) Presence of active myofascial trigger points Pain duration ≥ 3 months Pain intensity ≥ 4 on the Visual Analog Scale (VAS) Trigger points located in accessible muscles No trigger point injection in the affected area within the past 3 months Ability and willingness to provide informed consent Willingness to comply with study procedures and follow-up visits\n\nExclusion Criteria:\n\nKnown allergy or hypersensitivity to lidocaine, sodium bicarbonate, or other amide-type local anesthetics Current use of anticoagulants or presence of bleeding disorders Local or systemic infection at or near the injection site History of fibromyalgia, cancer-related pain, or central pain syndromes Major psychiatric disorders (e.g., schizophrenia, severe depression) Recent trauma or surgery to the neck, shoulder, or back within the past 6 months Use of analgesics (e.g., NSAIDs, opioids) within 5 days prior to injection Severe systemic diseases (e.g., uncontrolled diabetes, liver failure, kidney failure, severe cardiovascular disease)\n\n\\-","16 Years","70 Years",{"count":64,"type":22},30,[66],"NA","This study is designed to evaluate a method to improve the treatment of myofascial pain syndrome (MPS), a common condition that causes muscle pain, tenderness, and reduced movement due to the presence of trigger points in muscles.\n\nA commonly used treatment for this condition is the injection of a local anesthetic called lidocaine into these trigger points to relieve pain. However, the pain relief from lidocaine alone may be temporary.\n\nIn this study, we are investigating whether adding a small amount of sodium bicarbonate to lidocaine can improve its effectiveness. Sodium bicarbonate may reduce the pain during injection and help the anesthetic work faster and possibly last longer.\n\nParticipants in this study will be randomly assigned into one of two groups:\n\nOne group will receive lidocaine alone. The other group will receive lidocaine mixed with sodium bicarbonate.\n\nThe injection will be performed once into the painful muscle trigger points under sterile conditions.\n\nPain levels will be assessed using a simple pain scale, and muscle activity will be measured using a non-invasive technique called surface electromyography (sEMG), which records muscle electrical activity. These measurements will be taken before the injection, immediately after, and during follow-up visits.\n\nParticipants may experience mild discomfort during or after the injection, but all procedures are routinely used in clinical practice. Safety measures will be in place to manage any possible side effects.\n\nThe goal of this study is to determine whether the combined injection provides better pain relief, improves muscle function, and enhances patient comfort compared to lidocaine alone.",[69,70,71,72,28],"Myofacial Pain","Myofacial Pain Syndrome","Myofacial Pain Syndromes","Trigger Point Pain, Myofascial",[74,75,76,77,78,79,80,81,82,83],"lidocaine","Sodium Bicarbonate","Buffered Lidocaine","Trigger Point Injection","Surface Electromyography","Myofascial Trigger Points","Muscle Pain","Injection Pain","Muscle Activity","Musculoskeletal Pain","NOT_YET_RECRUITING","2026-05-01",{"date":87,"type":44},"2026-05-07",{"date":85,"type":22},{"date":90,"type":22},"2026-10-01",{"name":92,"class":51},"Cairo University",1,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":110,"leadSponsor":112,"locationsCount":93},"100633820","comparative-effectiveness-of-standard-and-modified-laser-therapy-in-myofascial-pain-management-100633820","NCT07531654","Comparative Effectiveness of Standard and Modified Laser Therapy in Myofascial Pain Management.","Comparative Effectiveness of Standard and Modified Laser Therapy in Myofascial Pain Management: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Diagnosis of myofascial temporomandibular disorder following the Research Diagnostic Criteria for Temporomandibular Disorders (RDC\u002FTMD).\n2. Participants eligible for inclusion in this study must not have received any previous laser therapy for the management of myofascial pain dysfunction syndrome or temporomandibular disorders like pharmacological therapy, physical therapy, manual techniques, and trigger point injections.\n3. No previous laser therapy for last 3 months.\n4. Pain localized to the masseter muscles.\n5. Pain lasting at least 3 months with a self-reported pain level of 6 or higher on a numerical rating scale (NRS).\n\nExclusion Criteria:\n\n1- Patients with TMJ pain, or those who had any previous treatment for TMD 2- Patients with any history of cervical or degenerative conditions, any surgery or trauma to the neck during last year 3- Previous treatment of MPDS during last year 4- Confirmed diagnosis of fibromyalgia or rheumatoid arthritis 5- Patients with dark skin tone or chubby face",{"count":102,"type":22},40,[66],"The goal of this clinical trial is to evaluate and compare the effectiveness of modified laser therapy versus conventional laser therapy in managing pain and mandibular function in patients with chronic myofascial pain syndrome involving the masseter muscles. The main questions it aims to answer are:\n\n1. Does high-intensity laser therapy (HILT) provide a greater reduction in pain intensity on a numerical rating scale (NRS) compared to low-level laser therapy (LLLT)?\n2. Does high-intensity laser therapy (HILT) provide greater improvement in functional outcomes, specifically maximal incisal opening, compared to low-level laser therapy (LLLT)?\n\nComparison Group:\n\nResearchers will compare the experimental group receiving High-Intensity Laser Therapy (HLLT) to a comparator group receiving Low-Level Laser Therapy (LLLT) to see if the modified high-intensity approach provides superior pain relief and improved mandibular movement.\n\nParticipants will:\n\n1. Be randomly assigned to either the HILT or LLLT treatment group.\n2. Undergo 12 laser irradiation sessions delivered over one month.\n3. Have laser energy applied directly to the trigger points of the masseter muscles during 5-minute sessions.\n4. Attend follow-up assessments at each session, and at intervals of 1, 3, and 6 months.\n5. Provide pain ratings using a numerical scale and have their maximal mouth opening measured by a caliper.",[28],"2026-04-09",{"date":108,"type":44},"2026-04-15",{"date":85,"type":22},{"date":111,"type":22},"2026-12-12",{"name":92,"class":51},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":93},"100622994","magnesium-sulfate-as-an-adjuvant-to-lidocaine-in-mpds-trigger-point-injections-assessed-by-vas-and-semg-100622994","NCT07390851","Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.","Evaluation of the Effect of Adding Magnesium Sulfate to Lidocaine in the Treatment of Myofascial Pain Dysfunction Syndrome Using Surface Electromyography (sEMG).(Randomized Clinical Trial)","Inclusion Criteria:\n\n1. Age between 18 and 70 years.\n2. Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS).\n3. Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius).\n4. Pain duration ≥ 3 months.\n5. Pain intensity ≥ 4 on the Visual Analog Scale (VAS).\n6. Noprior trigger point injection in the affected area within the past 3 months.\n7. Ability and willingness to provide informed consent.\n8. Compliance with study visits and procedures\n\nExclusion Criteria:\n\n1. Known allergy or hypersensitivity to Lidocaine, Magnesium Sulfate, or related agents.\n2. Current use of anticoagulants or history of bleeding disorders.\n3. Systemic or local infection at or near the injection site.\n4. History of fibromyalgia, central pain syndromes, or cancer-related pain.\n5. Major psychiatric illnesses (e.g., schizophrenia, severe depression).\n6. Recent surgery or trauma to the head, neck, or upper back (\\\u003C6 months).\n7. Use of analgesics (NSAIDs, opioids) within 5 days before intervention.\n8. Severe systemic diseases:- Uncontrolled diabetes mellitus- Liver or kidney failure- Severe cardiovascular conditions.",{"count":121,"type":22},28,[66],"Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone. The other group will receive trigger point injections of lidocaine combined with magnesium sulfate. The study aims to compare the effectiveness of both treatments in reducing pain and improving muscle function. Patients will be assessed using a pain scale (VAS) and surface electromyography (sEMG) to measure muscle activity.",[28],[126,127,128,78,129],"Trigger points injection","Myofascial Pain Dysfunction Syndrome (MPDS)","Magnesium Sulfate","Visual Analog Scale","2026-02-01",{"date":132,"type":44},"2026-02-05",{"date":134,"type":44},"2025-11-26",{"date":136,"type":22},"2026-11-26",{"name":92,"class":51},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":4},"100561811","phase-2-lidocaine-versus-magnesium-sulphate-in-management-of-myofascial-pain-dysfunction-syndrome-100561811","NCT06595017","Lidocaine Versus Magnesium Sulphate in Management of Myofascial Pain Dysfunction Syndrome","Evaluation of the Effect of Magnesium Sulfate Injection in Comparison to Lidocaine for Management of Myofascial Pain Dysfunction Syndrome: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age Limitations: Participants must be between 18 and 55 years old.\n* Chronic Pain Diagnosis: Individuals must have a diagnosis of chronic myofascial pain dysfunction syndrome (MPDS) affecting the face muscles, neck, shoulder, or upper back for a duration exceeding three months.\n* Trigger Point Recognition: Patients must show awareness of their pain when pressure is applied to identified myofascial trigger points, in accordance with established diagnostic guidelines.\n* Consent to Participate: Willingness to provide informed consent and engage in all aspects of the study.\n\nExclusion Criteria:\n\n* Previous Treatments: A history of receiving dry needling or pulsed radiofrequency therapy, or currently participating in other pain management treatments.\n* Recent Injury or Surgery: Any recent trauma, surgical procedures, or infections in the affected area within the past six months.\n* Medication Interference: Current or recent use of moderate to strong analgesics (e.g., tramadol, morphine) that could influence pain assessment.\n* Severe Health Conditions: Individuals with significant systemic illnesses (e.g., severe liver or kidney disease), blood clotting disorders, rheumatoid arthritis or epilepsy.\n* Mental Health: Presence of current psychiatric disorders, cognitive impairments, or inability to comply with the study protocol.","55 Years",{"count":147,"type":22},75,[149],"PHASE2","The goal of this clinical trial is to investigate the effectiveness of Magnesium Sulphate in the management of myofascial pain dysfunction syndrome in comparison to Lidocaine and Saline.\n\nA total of 75 patients suffering from myofascial pain dysfunction syndrome will be assigned into one of three groups, each with 25 patients.\n\nGroup A: (Saline) includes patients enrolled for Saline injection into the trigger points. Group B: (Magnesium Sulphate) includes patients enrolled for Magnesium Sulphate injection into the trigger points. Group C: (Lidocaine) includes patients who will be enrolled for Lidocaine injection into the trigger points The primary outcome that will be investigated is (pain with a visual analogue score), and secondary outcomes will be (maximum mouth opening between edges of upper and lower incisors with millimeters, electrical activity with Electromyography, and quality of life assessed using the Oral Health Impact Profile questionnaire) The outcomes will be assessed pre-injection, 1month after injection, 3months after injection, and 6 months after injection",[28],[153,154,155,156,157],"Myofascial pain dysfunction syndrome","Magnesium Sulphate","Lidocaine","Pain","Electromyography","2024-09-17",{"date":160,"type":44},"2024-09-19",{"date":162,"type":22},"2024-10-01",{"date":164,"type":22},"2025-11-30",{"name":166,"class":51},"Misr University for Science and Technology"]